Corporate Banner
Satellite Banner
Pharma Outsourcing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

ReNeuron to Receive Support from Foundation Fighting Blindness

Published: Wednesday, March 12, 2014
Last Updated: Wednesday, March 12, 2014
Bookmark and Share
Company receive support for its ReN003 retinal stem cell therapy candidate for treatment of retinitis pigmentosa.

ReNeuron Group plc has announced that its ReN003 retinal stem cell therapy candidate for retinitis pigmentosa is to receive support from the US-based Foundation Fighting Blindness (“the Foundation”), the world’s leading private source for inherited retinal disease research funding.

The Foundation has already played a key role in advancing ReNeuron’s ReN003 therapy through its funding of earlier pre-clinical work conducted by the Schepens Eye Research Institute, Massachusetts Eye and Ear (“Schepens”), ReNeuron’s principal US collaborator on the ReN003 programme.

The Foundation is planning to provide additional resources to ReNeuron and its collaborators in support of preparations for initial clinical trials with ReN003, including access to its network of expert pre-clinical and clinical advisers.

The Foundation is also providing further funding towards late pre-clinical work on the ReN003 programme conducted through Schepens.

ReNeuron is using its proprietary human retinal progenitor cells (hRPCs) as the basis of its ReN003 therapeutic candidate targeting retinitis pigmentosa, a group of hereditary diseases of the eye that lead to progressive loss of sight due to cells in the retina becoming damaged and eventually dying.

Pre-clinical studies have demonstrated that, when transplanted into the retina, hRPCs have the potential to rescue existing photoreceptors to help preserve vision, as well as mature into fully functional photoreceptors, allowing for the possibility of restored vision.

ReNeuron’s ReN003 therapy benefits from Orphan Drug Designation in both Europe and the US. The Company and its collaborators are currently completing late pre-clinical development of the ReN003 therapy, ahead of an initial clinical trial application planned for later this year.

Dr. Brian Mansfield, the Foundation’s Deputy Chief Research Officer, said: “ReNeuron is well positioned to advance its stem cell therapy for people with retinitis pigmentosa. We are excited about the prospects this treatment holds for potentially saving and restoring vision in these patients. This progress underscores the Foundation’s unique role in providing early support to advance promising research to the point of industry interest and further investment, while continuing to work with companies like ReNeuron to accelerate the path to the clinic.”

Dr. John Sinden, Chief Scientific Officer of ReNeuron, said: “We are delighted that the Foundation Fighting Blindness will be supporting the development of our ReN003 therapeutic candidate for retinitis pigmentosa. In particular, the Foundation’s extensive knowledge, experience and network of advisers will be invaluable to us as we look to progress the ReN003 programme into its clinical phase.”


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,100+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

ReNeuron Announces First Patient Treated in US Phase I/II Clinical Trial
Company has announced that the first patient has been treated with the Company’s cell therapy candidate for the blindness causing disease RP in a first-in-human US clinical trial.
Thursday, March 17, 2016
ReNeuron Receives Notice of Grant of Key US Patent on its Cell Cryopreservation Technology
Company has announced that it has received a notice of allowance for a key patent application covering its cell cryopreservation technology.
Tuesday, February 09, 2016
AGM Trading Update
CTX stem cell therapy candidate currently in a UK Phase II clinical trial.
Friday, September 25, 2015
Preliminary Results for the Year Ended 31 March 2015
Appointment of Olav Hellebø as CEO.
Saturday, July 11, 2015
FDA Grants Fast Track Designation to ReNeuron’s RP Cell Therapy Candidate
Approval to commence a Phase I/II clinical trial in the US with stem cell therapy candidate for RP.
Saturday, May 23, 2015
Long Term Clinical Data from PISCES Stroke Trial
Long term data continue to show good safety profile and evidence of sustained improvements in neurological status and limb function.
Saturday, April 18, 2015
ReNeuron Files Application to Commence Phase I/II Clinical Trial in the US
IND application to commence clinical trial for retinitis pigmentosa with hRPC therapy candidate.
Tuesday, April 14, 2015
ReNeuron AGM Trading Update
Results from the Phase I study with ReN009 announced in the first half of 2015.
Tuesday, September 09, 2014
Further Data from First Clinical Trial of ReNeuron’s Stem Cell Therapy to be Presented at Stroke Conference
Long term data continue to show good safety profile and evidence of sustained reductions in neurological impairment and spasticity.
Friday, May 16, 2014
ReNeuron Receives UK Regulatory Approvals
Company receive approvals to commence Phase II clinical trial in stroke and Phase I clinical trial in critical limb ischaemia.
Friday, March 28, 2014
Scientific News
Investigational Malaria Vaccine Protects Healthy U.S. Adults
Researchers at NIH have found that the malaria vaccine protected a small number of healthy, malaria-naïve adults in the U.S. from infection for more than one year after immunization.
AACR 2016: Cancer Immunotherapy and Beyond
At this year's meeting there was a palpable buzz around subjects ranging from microbiomics to the tumor microenvironment and cancer vaccines, big data to in vitro and in vivo modeling and drug delivery (to name just a few).
New Database for Sharing MS Clinical Trial Data
A new database containing nearly 2500 patient records from the placebo arms of nine multiple sclerosis (MS) clinical trials is now available for research by qualified investigators.
Study Finds Factors That May Influence Influenza Vaccine Effectiveness
Researchers at NIH have suggested that the long-held approach to predicting seasonal influenza vaccine effectiveness may need to be revisited.
BMS’s Opdivo Clinical Trial Shows Promise
Safety profile of the combination regimen from CheckMate -069 was consistent with previously reported studies and adverse events were managed using established safety algorithms.
Treatment of Common Prostate Cancer
Researchers at UTSW have found that the prostate cancer treatments suppress immune response and may promote relapse.
Cancer Drug Could Treat Blood Vessel Deformities
A drug currently being trialled in cancer patients could also be used to treat an often incurable condition that can cause painful blood vessel overgrowths inside the skin.
Structure of Crucial Enzyme Identified
Researchers at UTSW have determined the atomic structure of an enzyme that plays an essential role in cell division and better treatment of cancer.
New Immunotherapy Trial for Type 1 Diabetes
The search for a treatment for Type 1 diabetes (T1D) - which affects over 400,000 people in the UK – will be stepped up with the start of a new phase one clinical trial at Guy’s Hospital in London.
Recruitment of First Patient in Clinical Study
Company has announced recruitment of first patient in clinical study assessing Visco-ease with Beatson Cancer Centre for the treatment of RIX.
Scroll Up
Scroll Down
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,100+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!